Roivant raises $200M in equity financing, valuing company at $7B
The company, founded by Vivek Ramaswamy, anticipates topline data from six Phase III trials next year. It raised $1.1 billion last year in a round led by SoftBank.
The company, founded by Vivek Ramaswamy, anticipates topline data from six Phase III trials next year. It raised $1.1 billion last year in a round led by SoftBank.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
In a $1.05 billion deal, Veritas Capital, a New York City-based private equity firm, plans to buy GE's enterprise financial management, ambulatory care management and workforce management assets.
New investors taking part in the round included private equity firm Cross Creek Advisors and Madeira Tech Partners.
Despite the slowdown in private equity markets seen elsewhere in the early part of 2017, investment levels in digital health in 2017 to date are tracking on par with 2015 and 2016.
We find the most value in niche companies that can perform one particular service better than anyone else.
It plans to invest in 10 to 14 commercial-stage companies at $10 million to $20 million per business. Last year it co-founded surgical oncology startup Onkos Surgical.
These issues are a critical part of the national conversation on healthcare funding — funding which advances cures, drives economic growth and spurs technological innovation.
PaxVax will use the funding to pay off its debts, as well as launch a cholera vaccien called Vaxchora.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Managing director Bijan Salehizadeh points out that you can't overestimate the rate of adoption in healthcare.
The private equity firm's fourth fund has a hard cap of $500 million. It has a vast portfolio in the life sciences, including Cidara Therapeutics, T2 Biosystems and Seragon Pharmaceuticals.
Toronto’s Imperial Capital has just closed its fifth fund and is hoping to funnel some of the $295 million it raised into middle-market healthcare companies in the U.S. and Canada. The private equity firm focuses on acquiring and building healthcare, branded consumer product and business service companies with consistent cash flow and good growth opportunities. […]